The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Science from our Sisters

Science from our Sisters

February 1, 2007 • By Norra MacReady

  • Tweet
  • Email
Print-Friendly Version / Save PDF

RA Patients Respond to Drug Switching

You Might Also Like
  • Science from our Sisters
  • Science from our Sisters
  • Science from our Sisters
Explore This Issue
February 2007
Also By This Author
  • Dr. Wolfe & the National Data Bank for Rheumatic Diseases (NBD)
RA Patients Respond to Drug Switching

Most patients who switch from one anti–tumor necrosis factor a (anti–TNF-a) agent to a second for the treatment of RA experience good results, but those who discontinue the second drug usually do so for the same reasons they stopped the first, according to a study in Arthritis & Rheumatism (2007;56(1):13-20).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Anti–TNF-a agents have dramatically improved the management of severe RA. Unfortunately, as many as one-third of the patients who try these drugs derive no benefit from them, due either to inefficacy or intolerable adverse effects (AEs). If the first drug doesn’t work, many patients switch to a second anti–TNF-a agent on the rationale that it might be more effective due to differences in structure and site of action. This study is the first large-scale examination of the results of such a drug swap.

For a mean of 15 months, lead author Kimme Hyrich, MD, PhD, and colleagues at the University of Manchester (England) followed a prospective cohort of 6,739 RA patients drawn from a United Kingdom national registry of new patients starting anti–TNF-a therapy. During that time, 2,360 patients discontinued the initial drug, including 1,864 who discontinued because of lack of effect (n=841; 12%) or AEs (n=1,023; 15%). Of those patients, 503 and 353, respectively, switched to a second drug.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Overall, 73% of patients who switched to a second anti–TNF-a agent were still on the new therapy by the end of follow-up. However, 13% of the patients discontinued the second drug because of inefficacy, and 14% due to an adverse event. The patients who discontinued the second drug tended to do so for the same reasons they discontinued the first, whether that was inefficacy or toxicity.

“These findings suggest that, in those patients who fail to respond to their first agent, either because of an adverse effect or inefficacy, switching to a second anti–TNF agent may be a viable next option for some,” says Dr. Hyrich, clinical lecturer in the arthritis research campaign epidemiology unit at the University of Manchester. “It is also reassuring that the rate of discontinuation for an AE on a second agent was not increased in those patients who switched for inefficacy, suggesting, at least in the short term, that consecutive use of anti–TNF-a­­ agents does not place patients at an increased risk of AEs.”

Norra MacReady is a medical journalist based in southern California.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Rheumatoid Arthritis Tagged With: anti-TNF agent, DMARD, patient care, Research, Rheumatoid arthritisIssue: February 2007

You Might Also Like:
  • Science from our Sisters
  • Science from our Sisters
  • Science from our Sisters
  • Science from our Sisters

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.